Cytotoxic activity of some compounds towards human cancer cells.

No.	Comp.	In vitro cytotoxicity IC50 (μg mL−1)a
		HePG2	HCT-116	MCF-7	PC3
	DOX	4.50 ± 0.2	5.23 ± 0.3	4.17 ± 0.2	8.87 ± 0.6
A	NOR	14.30 ± 1.2	23.62 ± 1.8	20.47 ± 1.6	34.94 ± 2.5
B	MNP	38.53 ± 2.5	52.02 ± 3.1	45.25 ± 2.8	71.86 ± 3.4
C	IIIa	88.34 ± 4.2	92.13 ± 4.9	71.39 ± 3.5	>100
D	IVa	7.83 ± 0.6	10.48 ± 0.9	9.37 ± 0.7	15.29 ± 1.3
E	Va	32.22 ± 2.3	48.27 ± 2.8	25.16 ± 1.9	43.38 ± 2.9
F	Vb	11.61 ± 1.0	13.56 ± 1.2	14.85 ± 1.1	20.70 ± 1.6
G	Vc	23.09 ± 1.9	30.54 ± 2.3	21.20 ± 1.7	39.04 ± 2.5
H	IVj	18.57 ± 1.4	16.71 ± 1.4	19.64 ± 1.5	28.72 ± 2.1
I	Vd	26.24 ± 1.5	33.75 ± 1.9	25.45 ± 2.0	39.26 ± 2.4
J	Ve	36.18 ± 2.5	48.19 ± 1.2	29.30 ± 1.8	52.75 ± 2.6
K	Vf	49.68 ± 2.8	54.89 ± 3.1	34.18 ± 2.4	75.19 ± 3.5

^aIC50 (μg mL⁻¹): 1–10 (very strong). 11–20 (strong). 21–50 (moderate). 51–100 (weak) and above 100 (non-cytotoxic).